Company profile
Processa Pharmaceuticals, Inc.
NASDAQ:PCSABiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| HALOFUGINONE | phase2 | — | 2 | terminated |
| PCS-499 | phase2 | — | 3 | completed, terminated |
| RODUCITABINE | phase1_2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04800562 | phase2 | terminated | 2021-04-12 | 2023-02-28 | Processa Pharmaceuticals | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica |
| NCT06568692 | phase2 | recruiting | 2024-10-02 | 2026-09-01 | Processa Pharmaceuticals | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer |
| NCT04861987 | phase1 | completed | 2021-06-18 | 2024-06-12 | Processa Pharmaceuticals | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors |
| NCT03698864 | phase2 | completed | 2018-11-07 | 2020-02-25 | Processa Pharmaceuticals | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica |
| NCT02030067 | phase1_2 | completed | 2013-12-01 | 2019-07-01 | Processa Pharmaceuticals | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies |
FDA applications (0)
No records yet.